Mereo Book Value Per Share

MREO
 Stock
  

USD 0.80  0.0094  1.19%   

Mereo BioPharma Group fundamentals help investors to digest information that contributes to Mereo BioPharma's financial success or failures. It also enables traders to predict the movement of Mereo Stock. The fundamental analysis module provides a way to measure Mereo BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mereo BioPharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Mereo Book Value Per Share Analysis

Mereo BioPharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Book Value per Share 
 = 
Common Equity 
Average Shares 
More About Book Value Per Share | All Equity Analysis

Current Mereo BioPharma Book Value Per Share

    
  0.60 X  
Most of Mereo BioPharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mereo BioPharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Compare to competition

In accordance with the recently published financial statements, the book value per share of Mereo BioPharma Group is about 0.596 times. This is 135.06% lower than that of the Biotechnology sector and 100.24% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.97% higher than that of the company.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Mereo Fundamentals

About Mereo BioPharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mereo BioPharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mereo BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mereo BioPharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Mereo BioPharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run My Watchlist Analysis Now

   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo BioPharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Mereo BioPharma Piotroski F Score and Mereo BioPharma Altman Z Score analysis. Note that the Mereo BioPharma Group information on this page should be used as a complementary analysis to other Mereo BioPharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Mereo Stock analysis

When running Mereo BioPharma Group price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Mereo BioPharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
94.1 M
Return On Assets
(0.21) 
Return On Equity
(0.25) 
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo BioPharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.